

W. Eckelman and P. Richards

Brookhaven National Laboratory, Upton, New York

A procedure for the preparation of a ^{99m}Tc-labeled chelate of diethylenetriaminepentaacetic acid (^{99m}Tc-Fe DTPA) has previously been reported by this Laboratory (1). Chemical and biological stability studies as well as clinical evaluation all indicate that the ^{99m}Tc-Fe DTPA chelate is superior to ^{99m}Tc-pertechnetate for brain scanning in addition to being useful for kidney studies (2).

During recent studies involving the labeling of red blood cells with ^{99m}Tc-Sn citrate (3), we found that stannous ion is generally applicable for labeling chelates with technetium. This information has resulted in a rapid efficient procedure for the preparation of ^{99m}Tc-labeled DTPA (instant ^{99m}Tc-DTPA). The advantage of the stannous method is that all nonradioactive components can be pre-mixed in a single vial before the technetium activity is added. No final pH adjustment, further chemical manipulation or purification steps are required.

The preparation of a stock solution for about 40 patients is as follows:

To 1 ml of CaNa₃DTPA solution* (100 mg/ml):

1. Add 5 mg SnCl₂·2H₂O and heat at 100°C under N₂ for 15 min.
2. Dilute to 18 ml with sterile H₂O.
3. Adjust pH to 4.0 with HCl.
4. Dilute to 20 ml with sterile H₂O.
5. Purge solution with N₂ for 15 min.
6. Filter solution through a sterile 0.22-micron filter into evacuated vials, 1 ml of solution per vial.

To prepare solutions of instant ^{99m}Tc-DTPA solution, add 3 ml of pertechnetate saline solution to 1 ml for stock DTPA solution and mix for 1 min. No purification is necessary because the chelate is formed in greater than 95% yield. Strict adherence to the procedure described must be maintained because of the strong tendency of the stannous ion to hydrolyze.

Injection of a 2 ml quantity per patient results in the administration of a 2.5 mg DTPA (4.4 μM) and 125 μg SnCl₂·2H₂O (0.55 μM) per patient. This quantity contains less than 0.14% of the maximum daily dose of Na₃Ca DTPA (1.75 gm) that can be

used for treatment of heavy metal poisoning (4). Published toxicology data (5) indicate that the acute toxicity of nonprecipitant stannous citrate by intravenous injection into rabbits is of the order of sodium citrate so that the tin salts as such are not acutely toxic.

Stability of the stock solution and the instant ^{99m}Tc-DTPA was determined. The stock solution was stable for at least 7 days as indicated by preparation of ^{99m}Tc-DTPA with less than 5% impurity. The instant ^{99m}Tc-DTPA was stable for at least 4 hr as indicated by less than 5% impurity. Stability studies were conducted using gel chromatography (Sephadex G25) and paper chromatography (Whatman 3MM in saline).

Mice distribution studies gave results similar to those for ^{99m}Tc-Fe DTPA mentioned earlier (2). Human studies now in progress will be reported in the near future.

The development of a simplified procedure for preparing ^{99m}Tc-DTPA should promote the use of this valuable brain and kidney scanning agent, especially in hospitals with limited nuclear medicine facilities. This procedure is also conducive to pre-packaging in "kit form" by industrial manufacturers.

ACKNOWLEDGMENT

The authors would like to acknowledge the technical assistance of Miss Cecilia Motta and A. Macaulay. This work was performed under the auspices of the United States Atomic Energy Commission.

REFERENCES

1. RICHARDS P, ATKINS H: ^{99m}Technetium labeled compounds. *Jap Nucl Med* 7: 165-170, 1968 and *Proc 7th Ann Meeting Japanese Soc Nucl Med, Japan, 1967*
2. HAUSER W, ATKINS H, NELSON KG, et al: Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. *Radiology* 94: 679-684, 1970
3. ECKELMAN W, RICHARDS P, HAUSER W, et al: Technetium labeled red blood cells. *J Nucl Med*, in press.
4. CATSCH A: Zur Toxikologie der Diäthylentriamin-pentaessig sävre, Naunyn-Schmiedebergs. *Arch S. Exper Path u Pharmacol* 246: 316-329, 1964
5. SOLLMANN T: *A Manual of Pharmacology*, W. B. Saunders Co., Philadelphia, 1964, p. 1310

Received Sept. 16, 1970; original accepted Sept. 25, 1970.
For reprints contact: William Eckelman, Medical Radionuclide Group, Dept. of Applied Sciences, Brookhaven National Laboratory, Upton, N.Y. 11973.

* Available from the Div. of Biology and Medicine, U.S. Atomic Energy Commission, Washington, D.C.



Instant ^{99m}Tc -DTPA.

W Eckelman and P Richards

J Nucl Med. 1970;11:761.

This article and updated information are available at:
<http://jnm.snmjournals.org/content/11/12/761.citation>

Information about reproducing figures, tables, or other portions of this article can be found online at: <http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:
<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 1970 SNMMI; all rights reserved.